The effect of antihypertensive drugs on lipoprotein subfraction profile is still under investigation. In this study the effects of fixed combination of valsartan with either amlodipine (V --A) or hydrochlorothiazide (V --H) on low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL) subfraction profile of patients with stage 2 or 3 hypertension were assessed. A total of 60 drug-naive patients were randomized to either V --A (160/5 mg, n ¼ 30) or V --H (160/12.5 mg, n ¼ 30). At baseline as well as 16 weeks post-treatment analysis of the LDL and HDL subfraction profile was conducted by using LDL Lipoprint System. Both V --A and V --H effectively reduced blood pressure (BP) to similar levels. An increase in the cholesterol concentration of small-dense LDL subfractions (by 18.2%, Po0.05) was observed in the V --H group, whereas this parameter remained unchanged in the V --A group. Therefore, mean LDL particle size was decreased in the V --H group (from 267 ± 5 to 266 ± 5Å, Po0.05). HDL-Cholesterol (HDL-C) levels were reduced by 4.7% (Po0.05) in the V --H group, mirrored by a reduction in the cholesterol mass of small and intermediate HDL particles. In conclusion, despite similar reductions in BP, V --H combination may adversely affect serum lipids as well as LDL and HDL subfraction profile as compared with V --A.
INTRODUCTION
The risk of cardiovascular events increases at higher levels of blood pressure (BP). 1 It has been estimated that for every 20/10 mm Hg increase in BP, beginning at 115/75 mm Hg, the risk of cardiovascular death doubles. 1 First-line antihypertensive drugs either as monotherapy or in combination are efficacious in preventing cardiovascular events. 2, 3 According to the seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high BP (JNC 7) a combination of antihypertensive drugs is recommended for the management of patients with stage 2 or 3 hypertension. 4 JNC 7 guidelines also suggest that thiazides should be included in combination regimens in these patients. 4 At the same time, other combinations that do not include thiazides, such as combinations of angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors, with calcium channel blockers are alternative options. 5 The ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension) trial showed that a combination of benazepril with amlodipine is more effective compared with a combination of benazepril with hydrochlorothiazide in preventing cardiovascular events in 11 506 high-risk hypertensive patients. 6 Of interest, this differential capacity was evident despite comparable antihypertensive effects of these combinations. 6 Also, the ASCOT-BPLA (Anglo-Scandinavian Outcomes Trial-Blood Pressure Lowering Arm) study showed that amlodipine plus perindopril combination may be more effective compared with atenolol plus bendroflumethiazide in the prevention of cardiovascular events among high-risk hypertensive patients. 3 Of interest, this difference could not be entirely explained by better BP control. 3 In this context, many preclinical and small clinical studies with surrogate end points suggested that several antihypertensive drug categories, especially ARBs, angiotensin-converting enzyme inhibitors and calcium channel blockers may have benefits 'beyond BP control'. 7, 8 The identification of such properties could help the selection of an optimal combination of antihypertensive drugs.
Over the last decades, interest has increased regarding lipoprotein subfraction phenotype as a component of cardiovascular risk. Low-density lipoproteins (LDL) consist of heterogeneous populations of particles with respect to size, density and chemical composition. Several studies have shown that small-dense LDL (sdLDL) particles are more atherogenic than large and buoyant LDL (lbLDL), 9 and are associated with increased risk of coronary artery disease or stroke. 10, 11 High-density lipoprotein (HDL) also consists of a heterogeneous group of particles differing not only in size and density, but also in chemical composition and physiological function. The exact role that HDL particles of different size play in the pathogenesis of atherosclerosis is currently under investigation. It has been postulated that small HDL particles may be more potent in the process of reverse cholesterol transport than the large ones. 12 These particles may also be responsible for most of the anti-atherogenic, antioxidant and anti-inflammatory capacity of HDL. 12, 13 Several antihypertensive drug categories, including thiazides and b-blockers, may modify the serum lipid profile. 14, 15 Observational epidemiological studies indicate that the effects of antihypertensive drugs on lipids are large enough to account for substantial differences in the predicted incidence of cardiovascular disease.
14 Therefore, there is a need to expand our knowledge on the effect of antihypertensive drugs on lipoprotein subfraction profile.
Study endpoints
Primary endpoint: to compare the effects of V --A and V --H combinations on LDL and HDL subfraction profiles of patients with stage 2 or 3 hypertension. Secondary endpoint: to compare the effects of these combinations on BP as well as on lipid and non-lipid metabolic variables, including glucose homeostasis parameters, serum electrolyte and uric acid levels.
MATERIALS AND METHODS
Drug-naive patients with stage 2 or 3 hypertension attending the Outpatient Lipid Clinic of the University Hospital of Ioannina, Ioannina, Greece were enrolled in the present study. Diagnosis of stage 2 or 3 hypertension was made by abnormally high BP measurements: systolic BP 160 --179 mm Hg and/or diastolic BP 100 --109 mm Hg for stage 2 hypertension; systolic BP 180 --209 mm Hg and/or diastolic BP 110 --119 mm Hg for stage 3 hypertension, on the average of 2 or more properly measured, seated BP readings on each of two or more outpatient visits.
Exclusion criteria consisted of: (i) history of ischemic heart disease or any other vascular disease, (ii) impaired hepatic function (aminotransferase levels 42 Â the upper limit of normal, and/or history of chronic liver disease, such as cirrhosis), (iii) alcohol abuse, (iv) impaired renal function (serum creatinine 41.6 mg dl À1 , and/or a history of chronic renal disease, such as glomerulonephritis, chronic pyelonephritis, obstructive renal disease or proteinuria), (v) diabetes mellitus (present if a subject was treated for diabetes or by two separate fasting blood glucose measurements 4126 mg dl À1 ), (vi) thyroid dysfunction (thyroid stimulating hormone levels 45.0 mU l À1 ), and, (vii) any medical conditions that might preclude successful completion or the study protocol.
After a 6-week lead-in period in which all subjects followed a DASH (Dietary Approaches to Stop Hypertension) diet, 16 eligible patients were randomly allocated to open-label valsartan with either amlodipine 160/ 5 mg daily (V --A group) or hydrochlorothiazide 160/12.5 mg daily (V --H group) treatment. Compliance with study medication was assessed at week 16 with questionnaires and pill count; patients were considered compliant if they took 80 --100% of the allocated tablets. All patients gave their written informed consent and the study protocol was approved by the Institutional Ethics Committee.
Clinical evaluation
At baseline, as well as 16 weeks post-treatment body weight and height were measured in every individual to calculate body mass index (BMI ¼ body weight (in kg)/height (in m 2 )). Waist circumference was measured by the same investigator by placing a tape in a horizontal plane around the abdomen between the lower rib and iliac crest. The tape was snug without compressing the skin and parallel to the floor.
Laboratory investigations
Blood samples were obtained at baseline and after 16 weeks after a 12 hovernight fast (water consumption allowed). Glucose was measured by the hexokinase method and serum insulin concentrations by the AxSYM Insulin assay, which is based on the Microparticle Enzyme Immunoassay technology (Abbott Laboratories, Diagnostic Division, Chicago, IL, USA). 17 The Homeostasis Model Assessment, an epidemiological model for assessing insulin resistance (HOMA-IR) across glucose tolerance categories (HOMA-IR ¼ insulin (mU per ml) Â glucose (mg dl À1 ) Â 0.06/22.5) was used as a surrogate measure of insulin sensitivity. 17 Serum uric acid was determined by conventional methods. 17 
Serum lipoproteins and apolipoproteins
The concentrations of total cholesterol and triglycerides (TG) were determined enzymatically on the Olympus AU 600 clinical chemistry analyzer (Olympus Diagnostica, Hamburg, Germany). 17 High-densitylipoprotein cholesterol (HDL-C) was determined by a direct assay (Olympus Diagnostica, Hamburg, Germany). Low-density-lipoprotein cholesterol (LDL-C) was calculated by using the Friedewald's formula.
Apolipoprotein (apo) A1, apoB and apoE were measured with a Behring Nephelometer BN100, and reagents (antibodies and calibrators) from Dade Behring Holding GmbH (Liederbach, Germany).
LDL subfraction analysis
Blood samples were collected at baseline as well as after 16 weeks on treatment in EDTA containing tubes. Samples were centrifuged at 3000 r.p.m. for 15 min and stored at À80 1C until analysis at the end of the study. LDL subclass analysis was performed electrophoretically by the use of high-resolution 3% polyacrylamide gel tubes and the Lipoprint LDL System (Quantimetrix Co, Redondo Beach, CA, USA), according to the manufacturer's instructions, as we have previously described. 18 Briefly, 25 ml of sample was mixed with 200 ml of Lipoprint Loading Gel and placed upon the upper part of the 3% polyacrylamide gel. After 30 min of photopolymerisation at room temperature, electrophoresis was performed for 60 min with 3 mA for each gel tube. Each electrophoresis chamber involved two quality controls (sample provided by the manufacturer). For quantification, scanning was performed with a ScanMaker 8700 digital scanner (Mikrotek, Co, Hsinchu, Taiwan) connected to an iMac personal computer (Apple Computer Inc, Cupertino, CA, USA). After scanning, the electrophoretic mobility (R f ) and the area under the curve were calculated qualitatively and quantitatively with the Lipoprint LDL System Template and the Lipoware software (Quantimetrix, Co), respectively. In this method very low-density lipoprotein (VLDL) remains at the origin retention factor (R f ) ¼ 0.0, whereas HDL migrates at the front (R f ¼ 1.0). In between several bands can be detected: MID bands C, B and A, which correspond mainly to intermediate density lipoprotein, as well as up to 7 LDL bands. The LDL1 and LDL2 bands correspond to lbLDL particles, whereas bands LDL3 to LDL7 correspond to sdLDL particles. The cholesterol mass (in mg dl
À1
) of each lipoprotein subfraction, the mean LDL particle size (in Å) and the proportion (%) of the cholesterol mass of sdLDL subfractions (LDL3 to LDL7) over the total LDL-C mass were determined.
HDL subfraction analysis
The cholesterol content of HDL subfractions was determined electrophoretically by the use of high-resolution 3% polyacrylamide gel tubes and the Lipoprint HDL System as previously described by us. 19 Briefly, 25 ml of sample was mixed with 300 ml of Lipoprint Loading Gel and placed upon the upper part of the high resolution 3% polyacrylamide gel. After 30 min of photopolymerization in room temperature, electrophoresis was performed for 50 min with 3 mA for each gel tube. After electrophoresis, VLDL and LDL remained in the origin (R f ¼ 0.0), whereas albumin migrated at the front (R f ¼ 1.0). In between, up to nine bands of HDL (HDL1 to HDL9) can be detected whose 
Statistical analysis
It was estimated that a sample size of 54 would give a 95% power to detect a 15% difference in the change of mean LDL particle size between the two groups at an a of 0.05. We included 60 patients allowing for a drop-out rate of B10%. Preliminary analysis was performed to ensure no violation of the assumptions of linearity and normality. The Shapiro --Wilk test was used to evaluate whether each parameter followed a Gaussian distribution. Data are expressed as mean ± s.d., except for non-Gaussian parameters, which are presented as median (range). Differences of study parameters between baseline and post-treatment values were evaluated by paired samples t-test (or Wilcoxon's rank test for non-Gaussian parameters). Analysis of covariance, adjusted for baseline values, was used for comparisons between treatment groups.
After log-transforming non-Gaussian variables, Pearson's correlation coefficients were used to describe the relationship of post-treatment change in the mean LDL particle size as well as in the cholesterol concentration of sdLDL particles and HDL-C levels with age, sex, waist circumference, body mass index (BMI), HOMA-IR, lipids and apolipoprotein levels, as well as with post-treatment changes in these variables (univariate analysis). Stepwise multivariate linear regression analysis was performed to assess the independent contribution of the variables that resulted significantly associated in the univariate analysis.
Two-tailed significance was defined as Po0.05. All analyses were carried out with the Statistical Package for Social Sciences 16.0 (SPSS Inc., Chicago, IL, USA).
RESULTS

Demographics
A total of 66 patients were enrolled; 33 in the V --A group and 33 in the V --H group. In total, six patients, three in the V --A group and three in the V --H group, did not meet the inclusion criteria of the study after the dietary lead-in period and were excluded. The demographic and clinical characteristics of the study population are shown in Table 1 . Treatment groups were age-and sex-matched.
Safety and compliance All patients completed the study protocol without any withdrawals. Mild peripheral edema was reported by three patients in the V --A group, which was not clinically relevant. Mean compliance was 490% during the study period.
Clinical evaluation
Baseline clinical parameters and post-treatment changes in the two groups are shown in Table 1 . V --A and V --H group had similar baseline clinical parameters. No significant alterations in BMI and waist circumference were noted in both patient groups. Similar decreases in BP levels were observed (Figure 1 ). Namely, a decrease in systolic BP by 15% (Po0.001 vs baseline) was noticed in the V --A group and by 18.1% (Po0.001 vs baseline) in the V --H group (P ¼ not significant for the comparison between groups). Diastolic BP was reduced by 18.3% (Po0.001 vs baseline) in the V --A group and by 18.6% (Po0.001 vs baseline) in the V --H group (P ¼ not significant for the comparison between groups). Heart rate did not change from baseline in either treatment group (Table 1) .
Non-lipid metabolic variables Baseline and post-treatment changes in non-lipid metabolic variables are shown in Table 1 . Baseline values of these variables were not significantly different between groups. Neither drug regimen significantly affected glucose homeostasis parameters, including HOMA-IR as well as fasting glucose and insulin levels. Clinically significant electrolyte changes were not recorded during follow-up in either treatment arm: serum sodium, calcium and magnesium levels did not change significantly from baseline by either drug combination; however, a mild, though significant, decrease in circulating potassium levels by 6.7% (Po0.01 vs baseline) was noted following V --H treatment, which was not clinically relevant. An increase in serum uric acid levels by 5.4% (Po0.05 vs baseline) was noted in the V --H group, which was not evident in the V --A group.
Lipoprotein and apolipoprotein levels Baseline values and post-treatment changes in lipoprotein and apo levels are shown in Table 2 . No significant changes in total cholesterol and LDL-C levels were observed in treatment groups. Likewise, apoA1 and apoB levels did not change significantly from baseline in either group.
TG-rich lipoproteins V --H treatment was associated with a small, though significant, increase in TG levels by 6.4%, whereas this parameter remained unchanged in the V --A group. In concert, a significant increase by 7.0% in the cholesterol concentration of the TG-rich VLDL levels was noted in the V --H group, which was not evident in the V --A group. Also, apoE levels were significantly increased by 7.1% in the V --H group, whereas it did not change significantly from baseline in the V --A group (Po0.05 for all comparisons between groups).
Cholesterol concentration of LDL particles, LDL-C relative distribution on LDL particles and mean LDL particle size The cholesterol mass of LDL particles and the relative distribution of LDL-C on LDL particles at baseline as well as 16 weeks posttreatment are shown in Table 2 . A significant increase in the cholesterol concentration of sdLDL particles by 18.2% was observed in the V --H group. In contrast, the cholesterol mass of intermediate density lipoprotein and lbLDL particles was significantly decreased by 9.1% and 4.1%, respectively, following V --H treatment. V --A treatment was not associated with any changes in the cholesterol mass of LDL particles (Po0.05 for all comparisons between groups). A decrease in the relative distribution of LDL-C on lbLDL and intermediate density lipoprotein particles along with an increase in the relative distribution of LDL-C on sdLDL particles was noted only in the V--H group. Consequently, a significant decrease in the mean LDL particle size was observed in the V --H group. In contrast, the relative distribution of LDL-C on LDL particles of different size and buoyancy did not significantly change from baseline in the V--A group. Therefore, no change in mean LDL particle size was noticed in this group (Po0.05 for the comparison with the V--A group).
Cholesterol concentration of HDL particles The effect of both treatment modalities on cholesterol mass of HDL particles is shown in Table 2 . V --A combination had no significant effect on either HDL-C levels or the cholesterol content of HDL particles. On the other hand, a small, though significant, decrease by 4.7% in HDL-C level was observed in the V --H group, which was attributed to a decrease in the cholesterol concentration of small and intermediate HDL particles by 7.3% and 5.2%, respectively. The cholesterol content of large HDL particles did not change from baseline in this group.
Correlations
The increase in the cholesterol concentration of sdLDL particles in the V --H group was positively correlated with the increase in TG levels (r ¼ 0.77, Po0.01), in apoE levels (r ¼ 0.40, Po0.05) as well as with the increase in the cholesterol content of VLDL particles (r ¼ 0.65, Po0.01). Likewise, the decrease in the mean size of LDL particles in this group was associated with the increase in TG levels (r ¼ 0.62, Po0.05) and in the cholesterol content of VLDL particles (r ¼ 0.74, Po0.01). Also, the decrease in HDL-C levels in the V --H group was correlated only with the increase in TG levels in this group (r ¼ 0.50, Po0.05).
In multivariate analysis, the increase in the cholesterol mass of VLDL particles was the only variable, which was independently correlated with the decrease in mean LDL particle size in the V --H group (b ¼ 0.868, Po0.05).
DISCUSSION
According to our results V --H combination adversely modified lipoprotein subfraction profile into a more atherogenic pattern in patients with stage 2 or 3 hypertension. On the other hand, V --A treatment exhibited a neutral effect on lipoprotein subfraction 
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LG Christogiannis et al profile. Indeed, V --H was associated with an increase in the cholesterol mass of the atherogenic sdLDL particles. Besides, patients receiving this combination exhibited a redistribution of LDL-C from lbLDL to intermediate density lipoprotein and sdLDL particles mirrored by a significant decrease in the mean LDL particle size. V --H treatment was also associated with a decrease in HDL-C levels and mostly with a decrease in the cholesterol mass of small HDL particles. Many of the adverse metabolic actions of V --H combination could be attributed to the use of a thiazide. 20 Thiazides increase TG levels and VLDL-C, along with significant increases in total cholesterol and LDL-C levels, by mechanisms that are poorly understood. 15, 21 For example, in 1139 Chinese hypertensive patients newly prescribed antihypertensive drugs, thiazide use was associated with increased risk for high total cholesterol levels (X6.2 mmol l À1 or 240 mg dl À1 ) compared with ARBs (odds ratio 3.670, 95% confidence intervals, 1.134 --11.876, P ¼ 0.030) after 4 --16 weeks of treatment. 22 Also, thiazides were associated with an adverse impact on insulin resistance. 21 These effects have been proved dose-dependent and the 12.5 mg per day of hydrochlorothiazide used in this study has been considered as likely to avoid metabolic disturbances. 21, 23 On the other hand, drugs acting on the renin --angiotensin --aldosterone system, including angiotensin-converting enzyme inhibitors and ARBs, may beneficially modify the lipid profile. Benazepril alone or in combination with amlodipine significantly increased HDL-C levels and decreased lipoprotein (a) levels compared with amlodipine monotherapy in 27 patients with type 2 diabetes after 36 weeks of treatment. 24 The increase in TG-rich lipoproteins as reflected by the increase in VLDL-C concentration may be the major mechanism to explain the redistribution of LDL-C from larger to sdLDL particles in the V --H group. Overproduction of large TG-rich VLDL particles could serve as a substrate for the production of sdLDL subfractions. 25 In such circumstances, a net exchange of TG from TG-rich large VLDL to LDL via cholesterol ester transfer protein ultimately leads to the production of sdLDL particles through the action of hepatic lipase. 25 This assumption is supported by a strong and independent correlation between the post-treatment decrease in LDL particle size and the increase in the cholesterol mass of VLDL particles in the V --H group.
It has been postulated that potassium depletion may adversely affect carbohydrate metabolism by either increasing insulin resistance or impairing insulin secretion through mechanisms, which are still under investigation. 26 In the present study, the decrease in serum potassium levels following V --H combination was not associated with any significant alterations in either fasting glucose levels or insulin resistance reflected by HOMA-IR levels. The small number of patients, the relatively short period of exposure to treatment as well as the potential insulin-sensitizing effects of valsartan could have accounted for the neutral effect of V --H treatment on glucose homeostasis. Furthermore, there is a tendency for ARBs to increase plasma potassium levels. 27 Therefore, post-treatment difference between treatment groups regarding circulating potassium levels may reflect a fall in the V --H group and a small rise in the V --A group. Also, despite good correlation with the hyperinsulinemic euglycemic clamp (the 'gold standard' for assessing insulin resistance) it is not clear whether HOMA-IR can detect minimal changes in insulin resistance. 28 Another study showed that fixed combination of olmesartan with amlodipine, but not with hydrochlorothiazide, may improve carbohydrate metabolism as reflected by a decrease in the insulin resistance index, HOMA-IR and fasting insulin levels. 8 The effect of antihypertensive treatment on LDL subfractions was investigated in few, small studies. It has been suggested that metoprolol decreases LDL particle size by increasing postprandial and fasting triglyceridemia and, in turn, hepatic production of VLDL. 29 On the other hand, doxazosin increased mean LDL particle size in non-diabetic and diabetic hypertensive patients. 30 Valsartan 80 mg per day by enhancing lipoprotein lipase production in adipocytes induced an increase in LDL particle size after 12 weeks of treatment in 55 hypertensive patients with type 2 diabetes. 31 However, 36-week treatment with benazepril or amlodipine alone or in combination did not significantly change LDL particle size in 27 patients with type 2 diabetes. 24 Thiazides normally exhibit a neutral effect on HDL-C levels with few reports of a slight decrease. 20, 32 ARBs also seem not to exert significant alterations in HDL-C levels with the exception of reports showing a mild increase. 20, 31 Also, the reduction in HDL-C levels together with the rise in TG levels could serve as potential 'indicator' of the increased sdLDL cholesterol concentration in this group. 33 A decrease in the cholesterol mass of small and intermediate HDL particles accounted for the reduction in HDL-C levels in the V --H group. In contrast, neither HDL-C levels nor the cholesterol concentration of HDL particles changed in the V --A group. To date, there is no universal agreement whether large or small HDL subpopulations should be considered as more anti-atherogenic. Epidemiological studies have revealed a predominance of small TG-rich, rather than large cholesterol-rich HDL particles among patients with coronary heart disease. 34 Other studies proposed the presence of large HDL particles to have larger predictive value for incident coronary events than HDL-cholesterol itself. 35 On the other hand, small HDL particles are responsible for the most anti-oxidant and anti-inflammatory potency of HDL, due to their enrichment in anti-atherogenic enzymes, like HDL-associated platelet activating factor acetylhydrolase, also referred to as lipoprotein-associated phospholipase A 2 , and paraoxonase-1. 12 As the emerging concept is that the quality of HDL particles may be more important than the quantity of HDL, the decrease in the cholesterol concentration of the smaller HDL particles following V --H treatment is not necessarily an adverse effect of this combination on HDL subfraction phenotype. This assumption would hold true only if the smaller HDL particles were considered more anti-atherogenic than the large ones.
As with LDL subfraction profile, there is a paucity of data regarding the effect of antihypertensive drugs on HDL subfraction profile. Penbutolol was associated with a decrease in the cholesterol content of the small HDL3 subfractions, and atenolol induced an increase in this parameter in 21 hypertensive men. 36 Furthermore, amlodipine or benazepril as monotherapy or their combination had no significant effect on the cholesterol concentration of both HDL2 and HDL3 subfractions in 27 patients with type 2 diabetes after 36 weeks of treatment. 24 The adverse effects of antihypertensive drugs on the lipoprotein subfraction profile could be partially compensated by treatment with statins. Statins reduce the cholesterol concentration of all LDL subfractions equally. 17, 33 However, potent statins at high doses were shown to increase LDL particle size in a manner that is positively correlated with baseline TG levels and insulin resistance and in parallel with the TG-lowering effect of statins. 17 Furthermore, mild-to-moderate increases in HDL-C levels associated with statin use could diminish the HDL-C lowering effect of antihypertensive drugs. We have previously shown that rosuvastatin 10 and 20 mg per day (for 12-weeks) dose-dependently increased HDL-C levels (by 3.4% and 5.3%, respectively, P ¼ 0.02 for the comparison between groups). This was mostly attributed to a dose-dependent increase in the cholesterol concentration of large HDL subfractions. 37 Limitations of the current study include its open-label design, the absence of a placebo group and its relatively short duration.
CLINICAL IMPLICATIONS
Considering the comparable BP lowering effects the two combinations in individuals with stage 2 or 3 hypertension, V --A may be preferable over V --H because of its neutral effect compared with the adverse impact of V --H on lipoprotein subfractions. This finding implies that fixed combinations of calcium channel blockers with ARBs rather than those with thiazides may contribute to further cardiovascular risk reduction as supported by the findings of the ACCOMPLISH trial. 6 Our findings are also consistent with the results of a recent study showing that fixed combination of olmesartan with amlodipine may be more efficacious than olmesartan with hydrochlorothiazide in reducing inflammatory markers, including tumor-necrosisfactor-a, interleukin(IL)-1b, IL-6, IL-8, as well as intercellularadhesion-molecule-1 and vascular-cell-adhesion molecule-1. 8 This differential effect was recorded despite similar effects of the 2 combinations on BP control and serum lipid profile. 8 
What is known about this topic
Lipoprotein subfraction profile is a marker of cardiovascular risk. Antihypertensive drugs exert differential effects on serum lipid profile.
There is a need to expand our knowledge on the effect that antihypertensive drugs (including fixed combinations) exert on lipoprotein subfraction profile.
What this study adds
The fixed combination of valsartan with hydrochlorothiazide (V --H) decreased mean LDL particle size in stage 2 or 3 hypertensives. The same combination produces a small though significant decrease in HDL-C levels mirrored by a reduction in the cholesterol mass of smaller HDL particles. The fixed combination of valsartan with amlodipine (V --A) had a neutral effect on lipoprotein subfraction profile.
